Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Review

Metastasis review: from bench to bedside

Authors: Ali Mohammad Alizadeh, Sadaf Shiri, Sadaf Farsinejad

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

Cancer is the final result of uninhibited cell growth that involves an enormous group of associated diseases. One major aspect of cancer is when cells attack adjacent components of the body and spread to other organs, named metastasis, which is the major cause of cancer-related mortality. In developing this process, metastatic cells must successfully negotiate a series of complex steps, including dissociation, invasion, intravasation, extravasation, and dormancy regulated by various signaling pathways. In this review, we will focus on the recent studies and collect a comprehensive encyclopedia in molecular basis of metastasis, and then we will discuss some new potential therapeutics which target the metastasis pathways. Understanding the new aspects on molecular mechanisms and signaling pathways controlling tumor cell metastasis is critical for the development of therapeutic strategies for cancer patients that would be valuable for researchers in both fields of molecular and clinical oncology.
Literature
1.
Jemal A et al. Global cancer statistics. CA: Cancer J Clin. 2011;61(2):69–90.
2.
Jonsson B, Wilking N. A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007;18:1–78.
3.
Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer. 2007;110(8):1665–76.PubMed
4.
Khan N, Mukhtar H. Cancer and metastasis: prevention and treatment by green tea. Cancer Metastasis Rev. 2010;29(3):435–45.PubMedCentralPubMed
5.
Weigelt B, Peterse JL, Van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602.PubMed
6.
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789–99.PubMed
7.
Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMed
8.
Liotta LA, Kohn EC. Cancer’s deadly signature. Nat Genet. 2003;33(1):10–1.PubMed
9.
Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.PubMed
10.
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42.PubMed
11.
Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–84.PubMed
12.
Chung LW et al. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005;173(1):10–20.PubMed
13.
Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006;25(4):573–87.PubMed
14.
Weinberg RA. Is metastasis predetermined? Mol Oncol. 2007;1(3):263–4.PubMed
15.
Hyoudou K et al. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase quantitative analysis with firefly luciferase-expressing melanoma cells. Clin Cancer Res. 2004;10(22):7685–91.PubMed
16.
Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235(4787):442–7.PubMed
17.
Leong SP et al. Clinical patterns of metastasis. Cancer Metastasis Rev. 2006;25(2):221–32.PubMed
18.
Tuttle TM. Technical advances in sentinel lymph node biopsy for breast cancer. Am Surg. 2004;70(5):407–13.PubMed
19.
Pepper MS et al. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 2003;314(1):167–77.PubMed
20.
Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathmechdis Mech Dis. 2008;3:221–47.
21.
Brooks SA et al. Molecular interactions in cancer cell metastasis. Acta Histochemica. 2010;112(1):3–25.PubMed
22.
Spano D, et al. Molecular networks that regulate cancer metastasis. in Seminars in cancer biology. 2012. Elsevier.
23.
24.
Chambers AF, Groom AC, MacDonald IC. Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.PubMed
25.
Meighan CM, Schwarzbauer JE. Temporal and spatial regulation of integrins during development. Curr Opin Cell Biol. 2008;20(5):520–4.PubMedCentralPubMed
26.
van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res/Rev Mutat Res. 2011;728(1):23–34.
27.
Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2):118–32.PubMed
28.
Engers R, Gabbert HE. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol. 2000;126(12):682–92.PubMed
29.
Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126(3):589–98.PubMed
30.
31.
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91–100.PubMed
32.
Angst BD, Marcozzi C, Magee AI. The cadherin superfamily: diversity in form and function. J Cell Sci. 2001;114(4):629–41.PubMed
33.
Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005;6(8):622–34.PubMed
34.
Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251(5000):1451–5.PubMed
35.
Kashima T et al. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer. 2003;104(2):147–54.PubMed
36.
Shapiro L, Weis WI. Structure and biochemistry of cadherins and catenins. Cold Spring Harbor Perspect Biol. 2009;1(3):a003053.
37.
Mohamet L.Hawkins K. and Ward C.M. Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis. Journal of oncology, 2010. 2011.
38.
Li L, Bennett S, Wang L. Role of E-cadherin and other cell adhesion molecules in survival and differentiation of human pluripotent stem cells. Cell Adh Migr. 2012;6(1):59–70.PubMedCentralPubMed
39.
Beavon I. The E-cadherin–catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer. 2000;36(13):1607–20.PubMed
40.
Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 2009;34(4):881–95.PubMed
41.
Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol. 1995;7(5):619–27.PubMed
42.
Provost E, Rimm DL. Controversies at the cytoplasmic face of the cadherin-based adhesion complex. Curr Opin Cell Biol. 1999;11(5):567–72.PubMed
43.
Nagafuchi A. Molecular architecture of adherens junctions. Curr Opin Cell Biol. 2001;13(5):600–3.PubMed
44.
Ozawa M, Ringwald M, Kemler R. Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc Natl Acad Sci U S A. 1990;87(11):4246–50.PubMedCentralPubMed
45.
Hazan RB et al. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014(1):155–63.PubMed
46.
47.
Niessen CM, Leckband D. Tissue organization by cadherin adhesion molecules: dynamic molecular and cellular mechanisms of morphogenetic regulation. Physiol Rev. 2011;91(2):691–731.PubMedCentralPubMed
48.
Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996;84(3):345–57.PubMed
49.
Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosom Cancer. 2002;34(3):255–68.PubMed
50.
51.
Zhao D et al. Derivation and characterization of hepatic progenitor cells from human embryonic stem cells. PLoS One. 2009;4(7):e6468.PubMedCentralPubMed
52.
Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 2001;61(9):3819–25.PubMed
53.
Ramis-Conde I et al. Multi-scale modelling of cancer cell intravasation: the role of cadherins in metastasis. Phys Biol. 2009;6(1):016008.PubMed
54.
Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development. 1988;102(4):639–55.PubMed
55.
Hazan RB et al. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148(4):779–90.PubMedCentralPubMed
56.
De Wever O et al. Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-β or wounding. J Cell Sci. 2004;117(20):4691–703.PubMed
57.
Islam S et al. Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion. J Cell Biol. 1996;135(6):1643–54.PubMed
58.
Tomita K et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000;60(13):3650–4.PubMed
59.
Hsu M et al. Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci. 2000;113(Pt 9):1535–42.PubMed
60.
Shintani Y et al. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J Cell Biol. 2008;180(6):1277–89.PubMedCentralPubMed
61.
Augustine CK et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res. 2008;68(10):3777–84.PubMed
62.
Beasley GM et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer. 2009;115(20):4766–74.PubMed
63.
Tanaka H et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010;16(12):1414–20.PubMedCentralPubMed
64.
65.
Pećina-Šlaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 2003;3(1):17.PubMedCentralPubMed
66.
67.
Pinho SS et al. Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell Mol Life Sci. 2011;68(6):1011–20.PubMed
68.
Van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756–88.PubMed
69.
Jiang W. E‐cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surg. 1996;83(4):437–46.PubMed
70.
Larue L et al. A role for cadherins in tissue formation. Development. 1996;122(10):3185–94.PubMed
71.
Luo J, Lubaroff DM, Hendrix MJ. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res. 1999;59(15):3552–6.PubMed
72.
Hsu M-Y et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol. 2000;156(5):1515–25.PubMedCentralPubMed
73.
Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22(42):6524–36.PubMed
74.
Vleminckx K et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66(1):107–19.PubMed
75.
Riethmacher D, Brinkmann V, Birchmeier C. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc Natl Acad Sci U S A. 1995;92(3):855–9.PubMedCentralPubMed
76.
Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev. 1996;10(8):985–96.PubMed
77.
Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28(1–2):151–66.PubMed
78.
Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis 1. Endocr Rev. 2000;21(2):115–37.PubMed
79.
Bennett J, Moffatt S, Horton M. Cell adhesion molecules in human osteoblasts: structure and function. 2001.
80.
Ferrari SL et al. A role for N‐cadherin in the development of the differentiated osteoblastic phenotype. J Bone Miner Res. 2000;15(2):198–208.PubMed
81.
Hippo Y et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 2001;61(3):889–95.PubMed
82.
Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010;29(1):223–37.PubMed
83.
Gahmberg CG et al. Regulation of integrin activity and signalling. Biochim Biophys Acta (BBA)-Gen Subj. 2009;1790(6):431–44.
84.
Plow EF et al. Ligand binding to integrins. J Biol Chem. 2000;275(29):21785–8.PubMed
85.
Takagi J et al. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002;110(5):599–611.PubMed
86.
87.
Sastry SK, Burridge K. Focal adhesions: a nexus for intracellular signaling and cytoskeletal dynamics. Exp Cell Res. 2000;261(1):25–36.PubMed
88.
Berman A, Kozlova N, Morozevich G. Integrins: structure and signaling. Biochemistry (Moscow). 2003;68(12):1284–99.
89.
90.
Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–87.PubMed
91.
92.
White DE, Muller WJ. Multifaceted roles of integrins in breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2007;12(2–3):135–42.PubMed
93.
Janik ME, Lityńska A, Vereecken P. Cell migration—the role of integrin glycosylation. Biochim Biophys Acta (BBA)-Gen Subj. 2010;1800(6):545–55.
94.
Chung J, Kim TH. Integrin‐dependent translational control: implication in cancer progression. Microsc Res Tech. 2008;71(5):380–6.PubMed
95.
Schlaepfer DD, Jones K, Hunter T. Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol Cell Biol. 1998;18(5):2571–85.PubMedCentralPubMed
96.
Liapis H, Flath A, Kitazawa S. Integrin [alpha] v [beta] 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996;5(2):127–35.PubMed
97.
Pawelek JM, Chakraborty AK. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer. 2008;8(5):377–86.PubMed
98.
Aumailley M et al. Altered synthesis of laminin 1 and absence of basement membrane component deposition in (beta) 1 integrin-deficient embryoid bodies. J Cell Sci. 2000;113(2):259–68.PubMed
99.
Brooks PC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 1996;85(5):683–93.PubMed
100.
Deryugina EI et al. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci. 1997;110(19):2473–82.PubMed
101.
He Y et al. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res. 2007;13(11):3115–24.PubMed
102.
Desgrosellier JS et al. An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009;15(10):1163–9.PubMedCentralPubMed
103.
Wang Y et al. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. J Drug Targeting. 2009;17(6):459–67.
104.
Meyer T, Marshall J, Hart I. Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer. 1998;77(4):530.PubMedCentralPubMed
105.
Rolli M et al. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(16):9482–7.PubMedCentralPubMed
106.
Nieswandt B et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59(6):1295–300.PubMed
107.
Tang BL, Ng EL. Rabs and cancer cell motility. Cell Motil Cytoskeleton. 2009;66(7):365–70.PubMed
108.
Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285(5430):1028–33.PubMed
109.
Morozevich GE et al. Implication of alpha5beta1 integrin in invasion of drug-resistant MCF-7/ADR breast carcinoma cells: a role for MMP-2 collagenase. Biochemistry (Mosc). 2008;73(7):791–6.
110.
Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science. 1986;233(4762):467–70.PubMed
111.
Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta. 2007;1775(1):163–80.PubMed
112.
Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discovery. 2010;9(10):804–20.PubMed
113.
Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.PubMedCentralPubMed
114.
Mullamitha SA et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res. 2007;13(7):2128–35.PubMed
115.
Nabors LB et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25(13):1651–7.PubMed
116.
Reardon DA et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(34):5610–7.PubMed
117.
MacDonald TJ et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26(6):919–24.PubMed
118.
Ricart AD et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res. 2008;14(23):7924–9.PubMedCentralPubMed
119.
Danen EH et al. Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin alpha 5 beta 1. J Biol Chem. 1995;270(37):21612–8.PubMed
120.
Khalili P et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006;5(9):2271–80.PubMed
121.
Cianfrocca ME et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer. 2006;94(11):1621–6.PubMedCentralPubMed
122.
Mulgrew K et al. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody. Abegrin Mol Cancer Ther. 2006;5(12):3122–9.PubMed
123.
Gutheil JC et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6(8):3056–61.PubMed
124.
McNeel DG et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res. 2005;11(21):7851–60.PubMed
125.
Hersey P et al. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother. 2005;54(3):208–18.PubMed
126.
Trikha M et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer. 2004;110(3):326–35.PubMed
127.
Chen Q et al. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis. 2008;25(2):139–48.PubMed
128.
Martin PL et al. Reviews preclinical safety and immune-modulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-alpha in cynomolgus macaques. J Immunotoxicol. 2005;1(3):131–9.PubMed
129.
Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 2003;9(6):263–8.PubMed
130.
McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol. 2002;14(5):581–6.PubMed
131.
Läubli H. and Borsig.L., Selectins promote tumor metastasis. in Seminars in cancer biology. 2010. Elsevier.
132.
Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996;88(9):3259–87.PubMed
133.
Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol. 2004;22:129–56.PubMed
134.
Lowe JB. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr Opin Cell Biol. 2003;15(5):531–8.PubMed
135.
Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:1–10.
136.
Sperandio M. Selectins and glycosyltransferases in leukocyte rolling in vivo. Febs J. 2006;273(19):4377–89.PubMed
137.
Köhler S et al. E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br J Cancer. 2009;102(3):602–9.PubMedCentralPubMed
138.
Ley K et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–89.PubMed
139.
Sallusto F et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708–12.PubMed
140.
Sipkins DA et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435(7044):969–73.PubMedCentralPubMed
141.
Mannori G et al. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res. 1995;55(19):4425–31.PubMed
142.
Witz IP. The selectin–selectin ligand axis in tumor progression. Cancer Metastasis Rev. 2008;27(1):19–30.PubMed
143.
Läubli H, Spanaus K-S, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009;114(20):4583–91.PubMed
144.
Barthel SR et al. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets. 2007;11(11):1473–91.PubMedCentralPubMed
145.
Preusser M et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathologica. 2012;123(2):205–22.PubMed
146.
Crockett-Torabi E. Selectins and mechanisms of signal transduction. J Leukocyte Biol. 1998;63(1):1–14.PubMed
147.
Burdick MM et al. HCELL is the major E- and L-selectin ligand expressed on LS174T colon carcinoma cells. J Biol Chem. 2006;281(20):13899–905.PubMed
148.
Gout S et al. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res. 2006;66(18):9117–24.PubMed
149.
Aychek T et al. E‐selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release. Int J Cancer. 2008;123(8):1741–50.PubMed
150.
Ludwig RJ et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004;64(8):2743–50.PubMed
151.
Borsig L et al. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia. 2011;13(5):445–52.PubMedCentralPubMed
152.
Soroka, V., Kasper C., and Poulsen F.M. Structural biology of NCAM, in structure and function of the neural cell adhesion molecule NCAM. 2010, Springer. p. 3-22.
153.
Wai Wong C, Dye DE, Coombe DR. The role of immunoglobulin superfamily cell dhesion molecules in cancer metastasis. Int J Cell Biol. 2012;2012:340296.PubMedCentralPubMed
154.
Barclay A.N. Membrane proteins with immunoglobulin-like domains—a master superfamily of interaction molecules. in Seminars in immunology. 2003. Elsevier.
155.
Maddaluno L et al. The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells. J Exp Med. 2009;206(3):623–35.PubMedCentralPubMed
156.
Garrido-Urbani S et al. Vascular and epithelial junctions: a barrier for leucocyte migration. Biochem Soc Trans. 2008;36(2):203–12.PubMed
157.
Francavilla C., Maddaluno L., and Cavallaro U. The functional role of cell adhesion molecules in tumor angiogenesis. in Seminars in cancer biology. 2009. Elsevier.
158.
Johnson JP et al. Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int J Cancer. 1997;73(5):769–74.PubMed
159.
Wu G-J et al. Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice. J Urol. 2011;185(4):1504–12.PubMed
160.
Zeng G-F, Cai S-X, Wu G-J. Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells. BMC Cancer. 2011;11(1):113.PubMedCentralPubMed
161.
Roland CL et al. ICAM-1 expression determines malignant potential of cancer. Surgery. 2007;141(6):705–7.PubMed
162.
Siesser PF, Maness PF. L1 cell adhesion molecules as regulators of tumor cell invasiveness. Cell Adh Migr. 2009;3(3):275–7.PubMedCentralPubMed
163.
Jezierska A, Matysiak W, Motyl T. ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit Basic Res. 2006;12(8):BR263–73.
164.
Deng C et al. Angiogenic effect of intercellular adhesion molecule-1. J Huazhong Univ Sci Technol. 2007;27:9–12.
165.
Kevil CG et al. Intercellular adhesion molecule-1 (ICAM-1) regulates endothelial cell motility through a nitric oxide-dependent pathway. J Biol Chem. 2004;279(18):19230–8.PubMed
166.
Gratzinger D, Barreuther M, Madri JA. Platelet–endothelial cell adhesion molecule-1 modulates endothelial migration through its immunoreceptor tyrosine-based inhibitory motif. Biochem Biophys Res Commun. 2003;301(1):243–9.PubMed
167.
Park S et al. PECAM-1 regulates proangiogenic properties of endothelial cells through modulation of cell-cell and cell-matrix interactions. Am J Physiol-Cell Physiol. 2010;299(6):C1468–84.PubMedCentralPubMed
168.
Gavert N et al. L1-CAM in cancerous tissues. Expert Opin Biol Ther. 2008;8(11):1749–57.PubMed
169.
Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10(7):445–57.PubMed
170.
Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46(7):1271–7.PubMed
171.
Fox SB et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 1994;54(16):4539–46.PubMed
172.
Richter U et al. The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation. Histochem Cell Biol. 2012;137(5):687–95.PubMed
173.
UNDERHILL C. CD44: the hyaluronan receptor. J Cell Sci. 1992;103(2):293–8.PubMed
174.
Lesley J, Hyman R, Kincade PW. CD44 and its interaction with extracellular matrix. Adv Immunol. 1993;54:271–335.PubMed
175.
Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4(1):33–45.PubMed
176.
Ishii S et al. CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen. Surg Oncol. 1993;2(4):255–64.PubMed
177.
Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol. 1992;116(3):817–25.PubMed
178.
Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35(3):211–31.PubMed
179.
Legg JW et al. A novel PKC-regulated mechanism controls CD44–ezrin association and directional cell motility. Nat Cell Biol. 2002;4(6):399–407.PubMed
180.
Lokeshwar V, Bourguignon L. Post-translational protein modification and expression of ankyrin-binding site (s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. J Biol Chem. 1991;266(27):17983–9.PubMed
181.
Iczkowski KA. Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res. 2011;3(1):1.PubMedCentral
182.
Shimizu Y et al. Dual role of the CD44 molecule in T cell adhesion and activation. J Immunol. 1989;143(8):2457–63.PubMed
183.
Trochon V et al. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer. 1996;66(5):664–8.PubMed
184.
Webb D et al. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science. 1990;249(4974):1295–7.PubMed
185.
Aruffo A et al. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61(7):1303–13.PubMed
186.
Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function and association with the malignant process. Adv Cancer Res. 1997;71:241–319.PubMed
187.
Naor D et al. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39(6):527–79.PubMed
188.
Wielenga VJ et al. CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Adv Cancer Res. 1999;77:169–87.
189.
Hsieh H et al. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Mol Pathol. 1999;52(1):25.PubMedCentralPubMed
190.
Seiter S et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med. 1993;177(2):443–55.PubMed
191.
Ayhan A, Tok EC, Bildirici I. Overexpression of CD44 variant 6 in human endometrial cancer and its prognostic significance. Gynecol Oncol. 2001;80(3):355–8.PubMed
192.
Tijink BM et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006;12(20 Pt 1):6064–72.PubMed
193.
Orian-Rousseau V, Ponta H. Adhesion proteins meet receptors: a common theme? Adv Cancer Res. 2008;101:63–92.PubMed
194.
Liu C et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17(2):211–5.PubMedCentralPubMed
195.
Sahai E. Illuminating the metastatic process. Nat Rev Cancer. 2007;7(10):737–49.PubMed
196.
Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147(5):992–1009.PubMed
197.
198.
Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol. 2004;16(1):14–23.PubMed
199.
Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med. 2007;13(12):535–41.PubMed
200.
Gray RS, Cheung KJ, Ewald AJ. Cellular mechanisms regulating epithelial morphogenesis and cancer invasion. Curr Opin Cell Biol. 2010;22(5):640–50.PubMedCentralPubMed
201.
Gaggioli C et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007;9(12):1392–400.PubMed
202.
Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer. 2003;3(12):921–30.PubMed
203.
Mandeville J, Lawson MA, Maxfield FR. Dynamic imaging of neutrophil migration in three dimensions: mechanical interactions between cells and matrix. J Leukocyte Biol. 1997;61(2):188–200.PubMed
204.
Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 2003;5(8):711–9.PubMed
205.
Rösel D et al. Up-regulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces. Mol Cancer Res. 2008;6(9):1410–20.PubMed
206.
Micuda S et al. ROCK inhibitors as emerging therapeutic candidates for sarcomas. Curr Cancer Drug Targets. 2010;10(2):127–34.PubMed
207.
Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362–74.PubMed
208.
Wyckoff JB et al. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol. 2006;16(15):1515–23.PubMed
209.
Sabeh F, Shimizu-Hirota R, Weiss SJ. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J Cell Biol. 2009;185(1):11–9.PubMedCentralPubMed
210.
Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discovery. 2006;5(9):785–99.PubMed
211.
212.
Boy R.G., et al. Enzymes/transporters, in Molecular imaging II. 2008, Springer. p. 131-143.
213.
214.
Woodward JK et al. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone. 2007;41(6):912–27.PubMed
215.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74.PubMed
216.
Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6(1):32–43.PubMed
217.
López-Otín C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol. 2002;3(7):509–19.PubMed
218.
López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007;7(10):800–8.PubMed
219.
Sympson C.J., Bissell M.J. ,and Werb Z. Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. in Seminars in cancer biology. 1995. NIH Public Access.
220.
Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000;291(2):113–35.PubMed
221.
Shim K-N et al. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol. 2007;42(2):120–8.PubMed
222.
Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarker s and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27(31):5287–97.PubMedCentralPubMed
223.
Chu D et al. Matrix metalloproteinase‐9 is associated with disease‐free survival and overall survival in patients with gastric cancer. Int J Cancer. 2011;129(4):887–95.PubMed
224.
Gerstein E et al. Comparative enzyme immunoassay of matrix metalloproteinases-2,-7,-9 and their tissue inhibitor-2 in tumors and plasma of patients with gastric cancer. Bull Exp Biol Med. 2009;148(6):899–902.PubMed
225.
Fanjul-Fernández M et al. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochimica et Biophysica Acta (BBA)-Molecular. Cell Res. 2010;1803(1):3–19.
226.
Lynch CC. Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone. 2011;48(1):44–53.PubMed
227.
Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochimica et Biophysica Acta (BBA)-Molecular. Cell Res. 2010;1803(1):55–71.
228.
Lambert E et al. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49(3):187–98.PubMed
229.
Remacle A et al. Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP. Oncogene. 2006;25(41):5648–55.PubMed
230.
Hua H et al. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011;68(23):3853–68.PubMed
231.
Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–73.PubMed
232.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67.PubMedCentralPubMed
233.
Hojilla CV, Wood GA, Khokha R. Metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res. 2008;10(2):205.PubMedCentralPubMed
234.
Kähäri V-M, Saarialho-Kere U. Trends in molecular medicine: matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999;31(1):34–45.PubMed
235.
Ala-aho R, Kähäri V-M. Collagenases in cancer. Biochimie. 2005;87(3):273–86.PubMed
236.
Husmann K et al. Matrix metalloproteinase 1 promotes tumor formation and lung metastasis in an intratibial injection osteosarcoma mouse model. Biochim Biophys Acta (BBA)-Mol Basis Dis. 2013;1832(2):p. 347–354.
237.
Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000;6(12):4823–30.PubMed
238.
Trivedi V et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell. 2009;137(2):332–43.PubMedCentralPubMed
239.
Vincenti MP et al. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev™ Eukaryot Gene Expr. 1996;6(4):391–411.
240.
Huntington JT et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem. 2004;279(32):33168–76.PubMed
241.
Nikkola J et al. High expression levels of collagenase‐1 and stromelysin‐1 correlate with shorter disease‐free survival in human metastatic melanoma. Int J Cancer. 2002;97(4):432–8.PubMed
242.
Iida J, McCarthy JB. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-β. Melanoma Res. 2007;17(4):205–13.PubMed
243.
Hotary KB et al. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell. 2003;114(1):33–45.PubMed
244.
Goerge T et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 2006;66(15):7766–74.PubMed
245.
Blackburn JS et al. A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene. 2009;28(48):4237–48.PubMedCentralPubMed
246.
247.
Kamel H et al. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours. J Obstet Gynaecol Can. 2010;32(6):580–6.PubMed
248.
Määttä M et al. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000;6(7):2726–34.PubMed
249.
Galis ZS et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75(1):181–9.PubMed
250.
Łukaszewicz-Zając M, Mroczko B, Szmitkowski M. Gastric cancer—the role of matrix metalloproteinases in tumor progression. Clin Chim Acta. 2011;412(19):1725–30.PubMed
251.
Ben-Yosef Y et al. Hypoxia of endothelial cells leads to MMP-2-dependent survival and death. Am J Physiol-Cell Physiol. 2005;289(5):C1321–31.PubMed
252.
McQuibban GA et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000;289(5482):1202–6.PubMed
253.
Duong TD, Erickson CA. MMP‐2 plays an essential role in producing epithelial‐mesenchymal transformations in the avian embryo. Dev Dyn. 2004;229(1):42–53.PubMed
254.
Chetty C et al. MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line. Oncogene. 2007;26(55):7675–83.PubMedCentralPubMed
255.
Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem. 2001;276(11):8403–8.PubMed
256.
López-Otín C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases. Cell Cycle. 2009;8(22):3657–62.PubMedCentralPubMed
257.
Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 2006;17(4):217–23.PubMed
258.
Väyrynen JP et al. Serum MMP‐8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. Int J Cancer. 2012;131(4):E463–74.PubMed
259.
Thirkettle S et al. Matrix metalloproteinase 8 (collagenase 2) induces the expression of interleukins 6 and 8 in breast cancer cells. J Biol Chem. 2013;288(23):16282–94.PubMedCentralPubMed
260.
Decock J et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007;67(21):10214–21.PubMed
261.
Stuelten CH et al. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β. J Cell Sci. 2005;118(10):2143–53.PubMed
262.
Hallett MA et al. Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer. Breast Cancer Res. 2013;15(1):R12.PubMedCentralPubMed
263.
Morini M et al. The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP‐9) activity. Int J Cancer. 2000;87(3):336–42.PubMed
264.
Watanabe H et al. Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. J Cell Sci. 1993;104(4):991–9.PubMed
265.
Coussens LM et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13(11):1382–97.PubMedCentralPubMed
266.
Hojilla C, Mohammed F, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer. 2003;89(10):1817–21.PubMedCentralPubMed
267.
Bhoopathi P et al. Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of β1-integrin, ERK, and NF-κB. J Biol Chem. 2008;283(3):1545–52.PubMedCentralPubMed
268.
Jordà M et al. Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor. J Cell Sci. 2005;118(15):3371–85.PubMed
269.
Xu D et al. Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res. 2010;70(17):6988–98.PubMedCentralPubMed
270.
Tester AM et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS One. 2007;2(3):e312.PubMedCentralPubMed
271.
Kim M-J et al. TNF-α induces expression of urokinase-type plasminogen activator and β-catenin activation through generation of ROS in human breast epithelial cells. Biochem Pharmacol. 2010;80(12):2092–100.PubMed
272.
Zhang S et al. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol: WJG. 2003;9(5):899–904.PubMed
273.
Wu ZS et al. Prognostic significance of MMP‐9 and TIMP‐1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122(9):2050–6.PubMed
274.
Mroczko B et al. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Color Dis. 2010;25(10):1177–84.
275.
Zhang M et al. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma. J Surg Oncol. 2011;103(3):243–7.PubMed
276.
Freije JM et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 1994;269(24):16766–73.PubMed
277.
Knäuper V et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem. 1996;271(29):17124–31.PubMed
278.
Cowell S et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J. 1998;331:453–8.PubMedCentralPubMed
279.
Johansson N et al. Collagenase‐3 (MMP‐13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during human fetal bone development. Dev Dyn. 1997;208(3):387–97.PubMed
280.
Ravanti L et al. Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor β via p38 mitogen-activated protein kinase. FASEB J. 2001;15(6):1098–100.PubMed
281.
Mitchell PG et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest. 1996;97(3):761.PubMedCentralPubMed
282.
McQuibban GA et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276(47):43503–8.PubMed
283.
Uitto V-J et al. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol. 1998;152(6):1489.PubMedCentralPubMed
284.
Zhang Y et al. Overexpression of tyrosine kinase B protein as a predictor for distant metastases and prognosis in gastric carcinoma. Oncology. 2008;75(1–2):17–26.PubMed
285.
Yamada T et al. Overexpression of MMP-13 gene in colorectal cancer with liver metastasis. Anticancer Res. 2010;30(7):2693–9.PubMed
286.
Mäkinen LK et al. Prognostic significance of matrix metalloproteinase‐2, ‐8, ‐9, and ‐13 in oral tongue cancer. J Oral Pathol Med. 2012;41(5):394–9.PubMed
287.
Kominsky SL et al. MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-β1. Clin Exp Metastasis. 2008;25(8):865–70.PubMed
288.
Hsu C-P, Shen G-H, Ko J-L. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer. Lung Cancer. 2006;52(3):349–57.PubMed
289.
Heikkilä P et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anti-Cancer Drugs. 2002;13(3):245–54.PubMed
290.
Luukkaa M et al. Association between high collagenase‐3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck. 2006;28(3):225–34.PubMed
291.
Wang J et al. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2013;17(4):427–35.PubMed
292.
Koshikawa N et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000;148(3):615–24.PubMedCentralPubMed
293.
Koshikawa N et al. Membrane-type matrix metalloproteinase-1 (MT1-MMP) is a processing enzyme for human laminin γ2 chain. J Biol Chem. 2005;280(1):88–93.PubMed
294.
Sadowski T et al. Matrix metalloproteinase 19 processes the laminin 5 gamma 2 chain and induces epithelial cell migration. Cell Mol Life Sci CMLS. 2005;62(7–8):870–80.PubMed
295.
Mañes S et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem. 1999;274(11):6935–45.PubMed
296.
Rorive S et al. Matrix metalloproteinase‐9 interplays with the IGFBP2–IGFII complex to promote cell growth and motility in astrocytomas. Glia. 2008;56(15):1679–90.PubMed
297.
Noë V et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001;114(1):111–8.PubMed
298.
Maretzky T et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc Natl Acad Sci U S A. 2005;102(26):9182–7.PubMedCentralPubMed
299.
Illman SA et al. Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci. 2006;119(18):3856–65.PubMed
300.
Koshikawa N et al. Membrane type 1-matrix metalloproteinase cleaves off the NH2-terminal portion of heparin-binding epidermal growth factor and converts it into a heparin-independent growth factor. Cancer Res. 2010;70(14):6093–103.PubMed
301.
Loechel F, Wewer UM. Activation of ADAM 12 protease by copper. FEBS Lett. 2001;506(1):65–8.PubMed
302.
Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol. 1995;7(5):728–35.PubMed
303.
Hawinkels LJ et al. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 2010;70(10):4141–50.PubMed
304.
Pozzi A et al. Elevated matrix metalloprotease and angiostatin levels in integrin α1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A. 2000;97(5):2202–7.PubMedCentralPubMed
305.
Chang J-H et al. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett. 2005;579(17):3601–6.PubMed
306.
Wen W et al. The generation of endostatin is mediated by elastase. Cancer Res. 1999;59(24):6052–6.PubMed
307.
308.
Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 2002;91(9):845–51.PubMed
309.
Limb GA et al. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol. 2005;166(5):1555–63.PubMedCentralPubMed
310.
Balbín M et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003;35(3):252–7.PubMed
311.
Gutiérrez-Fernández A et al. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res. 2008;68(8):2755–63.PubMed
312.
Acuff HB et al. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res. 2006;66(16):7968–75.PubMed
313.
Houghton AM et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006;66(12):6149–55.PubMed
314.
Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9–34.PubMed
315.
Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep. 2004;6(2):96–102.PubMed
316.
Bourboulia D. and Stetler-Stevenson.W.G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. in Seminars in cancer biology. 2010. Elsevier.
317.
Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J National Cancer Inst. 1994;86(4):299–304.
318.
Schrötzlmair F et al. Tissue inhibitor of metalloproteinases‐1‐induced scattered liver metastasis is mediated by host‐derived urokinase‐type plasminogen activator. J Cell Mol Med. 2010;14(12):2760–70.PubMedCentralPubMed
319.
Bigelow RL et al. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat. 2009;117(1):31–44.PubMed
320.
Guedez L et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998;102(11):2002.PubMedCentralPubMed
321.
Hayakawa T et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992;298(1):29–32.PubMed
322.
Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit Basic Res. 2009;15(2):RA32–40.
323.
Caterina JJ et al. Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2 (Timp-2) gene alters proMMP-2 activation. J Biol Chem. 2000;275(34):26416–22.PubMed
324.
Bigg HF et al. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem. 1997;272(24):15496–500.PubMed
325.
Liacini A et al. Induction of matrix metalloproteinase-13 gene expression by TNF-α is mediated by MAP kinases, AP-1, and NF-κB transcription factors in articular chondrocytes. Exp Cell Res. 2003;288(1):208–17.PubMed
326.
Rozanov DV et al. The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem. 2004;279(6):4260–8.PubMed
327.
Eccles SA et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 1996;56(12):2815–22.PubMed
328.
Prontera C et al. Inhibition of gelatinase A (MMP‐2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 1999;81(5):761–6.PubMed
329.
Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93(3):178–93.PubMed
330.
Scatena R. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Invest Drugs. 2000;9(9):2159–65.
331.
Liu J et al. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung Cancer. 2003;42(3):335–44.PubMed
332.
Hoffman A et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor—synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem. 2008;51(5):1406–14.PubMed
333.
Maquoi E et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res. 2004;10(12):4038–47.PubMed
334.
Lubbe WJ et al. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin Cancer Res. 2006;12(6):1876–82.PubMed
335.
Tao P et al. Matrix metalloproteinase 2 inhibition: combined quantum mechanics and molecular mechanics studies of the inhibition mechanism of (4-phenoxyphenylsulfonyl) methylthiirane and its oxirane analogue. Biochemistry. 2009;48(41):9839–47.PubMedCentralPubMed
336.
Krüger A et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res. 2005;65(9):3523–6.PubMed
337.
Bonfil RD et al. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism‐based selective gelatinase inhibitor. Int J Cancer. 2006;118(11):2721–6.PubMed
338.
Devy L et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009;69(4):1517–26.PubMed
339.
Rawlings ND, Barrett AJ. Families of serine peptidases. Methods Enzymol. 1993;244:19–61.
340.
Netzel-Arnett S et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 2003;22(2–3):237–58.PubMed
341.
Duffy MJ et al. Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988;62(3):531–3.PubMed
342.
Stepanova V, Tkachuk V. Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Moscow). 2002;67(1):109–18.
343.
Thummarati P et al. High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol: WJG. 2012;18(3):244.PubMedCentralPubMed
344.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.PubMed
345.
Ulisse S et al. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9(1):32–71.PubMed
346.
Dass K et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008;34(2):122–36.PubMed
347.
Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol. 2000;12(5):613–20.PubMed
348.
Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol. 1997;137(3):767–77.PubMedCentralPubMed
349.
Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res. 2003;415:S46–58.PubMed
350.
Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist’s view. Thromb Haemost-Stuttgart-. 2007;97(3):336.
351.
Pepper MS. Role of the matrix metalloproteinase and plasminogen activator–plasmin systems in angiogenesis. Arterioscler, Thromb, Vasc Biol. 2001;21(7):1104–17.
352.
Gondi CS et al. Downregulation of uPAR and uPA activates caspase mediated apoptosis, inhibits the PI3k/AKT pathway. Int J Oncol. 2007;31(1):19.PubMedCentralPubMed
353.
Prager GW et al. Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein. Blood. 2009;113(6):1383–90.PubMed
354.
Shetty S et al. Urokinase induces activation of STAT3 in lung epithelial cells. Am J Physiol-Lung Cell Mol Physiol. 2006;291(4):L772–80.PubMed
355.
Malinowsky K et al. uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases. Transl Oncol. 2012;5(2):98–IN3.PubMedCentralPubMed
356.
Ghamande SA et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008;111(1):89–94.PubMed
357.
Ellis V, Dano K. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J. 1993;296(Pt 2):505–10.PubMedCentralPubMed
358.
Schmitt M et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2011;11(6):617–34.PubMed
359.
Benes P, Vetvicka V, Fusek M. Cathepsin D—many functions of one aspartic protease. Crit Rev Oncol Hematol. 2008;68(1):12–28.PubMedCentralPubMed
360.
Liaudet-Coopman E et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett. 2006;237(2):167–79.PubMed
361.
Masson O et al. Pathophysiological functions of cathepsin D: targeting its catalytic activity versus its protein binding activity? Biochimie. 2010;92(11):1635–43.PubMed
362.
Fuseka M, Vetvicka V. Dual role of cathepsin D: ligand and protease. Biomed Papers. 2005;149(1):43–50.
363.
Baechle D et al. Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1 L. J Biol Chem. 2006;281(9):5406–15.PubMed
364.
Nirdé P et al. Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells. Oncogene. 2009;29(1):117–27.PubMedCentralPubMed
365.
Erdmann S et al. Inflammatory cytokines increase extracellular procathepsin D in permanent and primary endothelial cell cultures. Eur J Cell Biol. 2008;87(5):311–23.PubMed
366.
Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009;18(5):585–600.PubMedCentralPubMed
367.
368.
Sudhan DR, Siemann DW. Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clin Exp Metastasis. 2013;30(7):891–902.PubMed
369.
Ward C et al. Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One. 2010;5(9):e12543.PubMedCentralPubMed
370.
Burden RE et al. Inhibition of cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie. 2012;94(2):487–93.PubMed
371.
Dabrosin C, Johansson AC, Ollinger K. Decreased secretion of cathepsin D in breast cancer in vivo by tamoxifen: mediated by the mannose-6-phosphate/IGF-II receptor? Breast Cancer Res Treat. 2004;85(3):229–38.PubMed
372.
Vasiljeva O et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007;13(4):387–403.PubMed
373.
Elie BT et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie. 2010;92(11):1618–24.PubMed
374.
375.
Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci. 2008;29(1):22–8.PubMed
376.
Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6(10):764–75.PubMed
377.
Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Investig. 2010;120(10):3421–31.PubMedCentralPubMed
378.
Kosa’b J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul. 2002;42:285.
379.
Watts C. The endosome–lysosome pathway and information generation in the immune system. Biochimica et Biophysica Acta (BBA)-Proteins and. Proteomics. 2012;1824(1):14–21.
380.
Rothberg JM et al. Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment. Biochimica et Biophysica Acta (BBA)-Proteins and. Proteomics. 2012;1824(1):123–32.
381.
Dauth S et al. Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits. BMC Neurosci. 2011;12(1):74.PubMedCentralPubMed
382.
Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem. 2004;385(11):1017–27.PubMed
383.
Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta. 2004;342(1):41–69.PubMed
384.
Arvatz G et al. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev. 2011;30(2):253–68.PubMed
385.
Green KA, Lund LR. ECM degrading proteases and tissue remodelling in the mammary gland. Bioessays. 2005;27(9):894–903.PubMed
386.
387.
Reinheckel T et al. Differential impact of cysteine cathepsins on genetic mouse models of de novo carcinogenesis: cathepsin B as emerging therapeutic target. Front Pharmacol. 2012;3:133.PubMedCentralPubMed
388.
Mitchell BS. The proteasome—an emerging therapeutic target in cancer. N Engl J Med. 2003;348(26):2597–8.PubMed
389.
Kane RC et al. Velcade®: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508–13.PubMed
390.
Zavrski I et al. Proteasome: an emerging target for cancer therapy. Anti-Cancer Drugs. 2005;16(5):475–81.PubMed
391.
Kane RC et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13(18):5291–4.PubMed
392.
Chen D et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11(3):239.PubMedCentralPubMed
393.
Berenson JR et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006;24(6):937–44.PubMed
394.
Kane RC et al. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006;12(10):2955–60.PubMed
395.
Liotta LA, Kohn EC. The microenvironment of the tumour–host interface. Nature. 2001;411(6835):375–9.PubMed
396.
Hughes-Alford SK, Lauffenburger DA. Quantitative analysis of gradient sensing: towards building predictive models of chemotaxis in cancer. Curr Opin Cell Biol. 2012;24(2):284–91.PubMedCentralPubMed
397.
Onuffer JJ, Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci. 2002;23(10):459–67.PubMed
398.
Ebert LM, Schaerli P, Moser B. Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Mol Immunol. 2005;42(7):799–809.PubMed
399.
Kedrin D et al. Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia. 2007;12(2–3):143–52.PubMed
400.
401.
Wells A et al. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci. 2013;34(5):283–9.PubMedCentralPubMed
402.
do Carmo A et al. CXCL12/CXCR4 promotes motility and proliferation of glioma cells. Cancer Biol Ther. 2010;9(1):p. 56–65.
403.
Dai X et al. The CXCL12/CXCR4 autocrine loop increases the metastatic potential of non-small cell lung cancer in vitro. Oncol Lett. 2013;5(1):277–82.PubMedCentralPubMed
404.
Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119(9):2026–9.PubMed
405.
Dewan M et al. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006;60(6):273–6.PubMed
406.
Kato M et al. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res. 2003;5(5):R144–50.PubMedCentralPubMed
407.
Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 1998;20(1):41–8.PubMed
408.
Xue C et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res. 2006;66(1):192–7.PubMed
409.
Ma PC et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22(4):309–25.PubMed
410.
Micke P. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer. 2004;45:S163–75.PubMed
411.
Qian L-W et al. Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett. 2003;190(1):105–12.PubMed
412.
Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006;238(1):30–41.PubMed
413.
Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107(5):1761–7.PubMed
414.
Takebe N et al. Review of cancer-associated fibroblasts and therapies that interfere with their activity. Tumor Microenvironment Ther. 2013;1:19–36.
415.
Yin HL, Janmey PA. Phosphoinositide regulation of the actin cytoskeleton. Annu Rev Physiol. 2003;65(1):761–89.PubMed
416.
Hurley JH. Membrane binding domains. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of. Lipids. 2006;1761(8):805–11.
417.
Barber MA, Welch HC. PI3K and RAC signalling in leukocyte and cancer cell migration. Bull Cancer. 2006;93(5):10044–52.
418.
Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans. 2005;33:891–5.PubMed
419.
Bravo-Cordero JJ et al. A novel spatiotemporal RhoC activation pathway locally regulates cofilin activity at invadopodia. Curr Biol. 2011;21(8):635–44.PubMedCentralPubMed
420.
Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003;112(4):453–65.PubMed
421.
Mouneimne G et al. Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation. J Cell Biol. 2004;166(5):697–708.PubMedCentralPubMed
422.
Wilkinson S, Paterson HF, Marshall CJ. Cdc42–MRCK and Rho–ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol. 2005;7(3):255–61.PubMed
423.
Kopp F et al. Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer. 2014;13:16.PubMedCentralPubMed
424.
Kumar P et al. Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer. 2010;9:206.PubMedCentralPubMed
425.
Palmer TD et al. Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. Cancer Res. 2014;74(1):173–87.PubMedCentralPubMed
426.
Wang S et al. Study on invadopodia formation for lung carcinoma invasion with a microfluidic 3D culture device. PLoS One. 2013;8(2):e56448.PubMedCentralPubMed
427.
Wolf K et al. Compensation mechanism in tumor cell migration mesenchymal–amoeboid transition after blocking of pericellular proteolysis. J Cell Biol. 2003;160(2):267–77.PubMedCentralPubMed
428.
Thiery JP et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.PubMed
429.
Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012;24(2):277–83.PubMedCentralPubMed
430.
Wang W et al. Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Res. 2007;67(8):3505–11.PubMed
431.
Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009;26(4):273–87.PubMed
432.
Vignjevic, D. and Montagnac G. Reorganisation of the dendritic actin network during cancer cell migration and invasion. in Seminars in cancer biology. 2008. Elsevier.
433.
Buccione R, Caldieri G, Ayala I. Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev. 2009;28(1–2):137–49.PubMed
434.
Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010;8(5):629–42.PubMed
435.
Condeelis J.S. et al. Lamellipodia in invasion. in Seminars in cancer biology. 2001. Elsevier.
436.
Wang W et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res. 2002;62(21):6278–88.PubMed
437.
Vignjevic D et al. Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 2007;67(14):6844–53.PubMed
438.
Mongiu AK et al. Kinetic-structural analysis of neuronal growth cone veil motility. J Cell Sci. 2007;120(6):1113–25.PubMed
439.
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33.PubMed
440.
Khoury H et al. Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene. 2001;20(7):788–99.PubMed
441.
442.
Caldieri G et al. Invadopodia biogenesis is regulated by caveolin‐mediated modulation of membrane cholesterol levels. J Cell Mol Med. 2009;13(8b):1728–40.PubMed
443.
Kelly T et al. Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases. Clin Exp Metastasis. 1998;16(6):501–12.PubMed
444.
Tague SE, Muralidharan V, D’Souza-Schorey C. ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci U S A. 2004;101(26):9671–6.PubMedCentralPubMed
445.
Oxmann D et al. Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype. Oncogene. 2008;27(25):3567–75.PubMed
446.
Clark ES et al. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007;67(9):4227–35.PubMed
447.
Artym VV et al. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006;66(6):3034–43.PubMed
448.
Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904.PubMed
449.
Zervantonakis IK et al. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc Natl Acad Sci U S A. 2012;109(34):13515–20.PubMedCentralPubMed
450.
Quigley JP, Armstrong PB. Tumor cell intravasation Alu-cidated: the chick embryo opens the window. Cell. 1998;94(3):281–4.PubMed
451.
Wirtz D. Particle-tracking microrheology of living cells: principles and applications. Annu Rev Biophys. 2009;38:301–26.PubMed
452.
Yeung T et al. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell Mot Cytoskeleton. 2005;60(1):24–34.
453.
Baker EL, Bonnecaze RT, Zaman MH. Extracellular matrix stiffness and architecture govern intracellular rheology in cancer. Biophys J. 2009;97(4):1013–21.PubMedCentralPubMed
454.
Baker EL et al. Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential. Biophys J. 2010;99(7):2048–57.PubMedCentralPubMed
455.
Lee JS et al. Ballistic intracellular nanorheology reveals ROCK-hard cytoplasmic stiffening response to fluid flow. J Cell Sci. 2006;119(9):1760–8.PubMed
456.
Cross SE et al. Nanomechanical analysis of cells from cancer patients. Nat Nanotechnol. 2007;2(12):780–3.PubMed
457.
Swartz MA, Fleury ME. Interstitial flow and its effects in soft tissues. Annu Rev Biomed Eng. 2007;9:229–56.PubMed
458.
Mycielska ME, Djamgoz MB. Cellular mechanisms of direct-current electric field effects: galvanotaxis and metastatic disease. J Cell Sci. 2004;117(9):1631–9.PubMed
459.
Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer. 2011;11(7):512–22.PubMedCentralPubMed
460.
Roussos ET et al. Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci. 2011;124(13):2120–31.PubMedCentralPubMed
461.
Calvo F, Sahai E. Cell communication networks in cancer invasion. Curr Opin Cell Biol. 2011;23(5):621–9.PubMed
462.
Giampieri S et al. Localized and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11(11):1287–96.PubMedCentralPubMed
463.
Zijlstra A et al. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell. 2008;13(3):221–34.PubMedCentralPubMed
464.
Wyckoff JB et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649–56.PubMed
465.
Bekes EM et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol. 2011;179(3):1455–70.PubMedCentralPubMed
466.
Weis S et al. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004;167(2):223–9.PubMedCentralPubMed
467.
Bockhorn M, Jain RK, Munn LL. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol. 2007;8(5):444–8.PubMedCentralPubMed
468.
Wong SY, Hynes RO. Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle (Georgetown, Tex). 2006;5(8):812.
469.
Bockhorn M et al. Differential gene expression in metastasizing cells shed from kidney tumors. Cancer Res. 2004;64(7):2469–73.PubMed
470.
Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochimica et Biophysica Acta (BBA)-Reviews on. Cancer. 1990;1032(1):89–118.
471.
Nash G et al. Platelets and cancer. Lancet Oncol. 2002;3(7):425–30.PubMed
472.
473.
Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64.PubMed
474.
Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51.PubMed
475.
Nathan C. Metchnikoff’s legacy in 2008. Nat Immunol. 2008;9(7):695–8.PubMed
476.
Hao N-B et al. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012;2012:11.
477.
478.
Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263–6.PubMed
479.
480.
Goswami S et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005;65(12):5278–83.PubMed
481.
Wyckoff J et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64(19):7022–9.PubMed
482.
Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle (Georgetown, Tex). 2006;5(16):1760–71.
483.
Kitamura T et al. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet. 2007;39(4):467–75.PubMed
484.
van Kempen LC, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer. 2006;42(6):728–34.PubMed
485.
Cheng K, Xie G, Raufman J-P. Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol. 2007;73(7):1001–12.PubMedCentralPubMed
486.
Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67(11):5064–6.PubMed
487.
Tsutsui S et al. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep. 2005;14(2):425–31.PubMed
488.
Bolat F et al. Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. Vascular. 2006;14:15.
489.
Oosterling SJ et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol. 2005;207(2):147–55.PubMed
490.
DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27(1):11–8.PubMed
491.
Wang W et al. Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol. 2005;15(3):138–45.PubMed
492.
Condeelis J, Singer RH, Segall JE. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol. 2005;21:695–718.PubMed
493.
Yamaguchi H, Pixley F, Condeelis J. Invadopodia and podosomes in tumor invasion. Eur J Cell Biol. 2006;85(3):213–8.PubMed
494.
Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002;7(2):177–89.PubMed
495.
Ries, C.H., et al., Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell, 2014
496.
Ries CH et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846–59.PubMed
497.
Pyonteck SM et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–72.PubMed
498.
Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6(3):173–82.PubMed
499.
Phillipson M, Kubes P. The neutrophil in vascular inflammation. Nat Med. 2011;17(11):1381–90.PubMed
500.
Huh SJ et al. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010;70(14):6071–82.PubMedCentralPubMed
501.
Cools-Lartigue J et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Investig. 2013;123(8):3446–58.PubMedCentral
502.
Teramukai S et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45(11):1950–8.PubMed
503.
McDonald B et al. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer. 2009;125(6):1298–305.PubMed
504.
Spicer JD et al. Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells. Cancer Res. 2012;72(16):3919–27.PubMed
505.
Auguste P et al. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol. 2007;170(5):1781–92.PubMedCentralPubMed
506.
Liang S et al. Effects of the tumor-leukocyte microenvironment on melanoma–neutrophil adhesion to the endothelium in a shear flow. Cell Mol Biol. 2008;1(2–3):189–200.
507.
Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103(33):12493–8.PubMedCentralPubMed
508.
Lynn KD, Roland CL, Brekken RA. VEGF and pleiotrophin modulate the immune profile of breast cancer. Cancers. 2010;2(2):970–88.PubMedCentralPubMed
509.
Lee AM et al. Modeling and simulation of procoagulant circulating tumor cells in flow. Front Oncol. 2012;2:184.
510.
Mantovani A et al. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMed
511.
Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci. 2008;13(2):5094–107.PubMed
512.
513.
Kumar D et al. Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. Bioorg Med Chem. 2002;10(12):3997–4004.PubMed
514.
Combe B. Thalidomide: new indications? Joint Bone Spine. 2001;68(6):582–7.PubMed
515.
516.
Keifer JA et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276(25):22382–7.PubMed
517.
Laber DA et al. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer Biol Ther. 2007;6(6):840–5.PubMed
518.
Zidi I et al. TNF-alpha and its inhibitors in cancer. Med Oncol. 2010;27(2):185–98.PubMed
519.
Zavadil J, Böttinger EP. TGF-β and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764–74.PubMed
520.
Giampieri S, Pinner S, Sahai E. Intravital imaging illuminates transforming growth factor β signaling switches during metastasis. Cancer Res. 2010;70(9):3435–9.PubMedCentralPubMed
521.
Yang L et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+ CD11b + myeloid cells that promote metastasis. Cancer Cell. 2008;13(1):23–35.PubMedCentralPubMed
522.
Tseng D, Vasquez-Medrano DA, Brown JM. Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. Br J Cancer. 2011;104(12):1805–9.PubMedCentralPubMed
523.
Redjal N et al. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006;12(22):6765–71.PubMed
524.
525.
Zeng Z et al. SDF-1 inhibition using Spiegelmer® Nox-A12 as a novel strategy for targeting AML cells within their BM microenvironment. Blood. 2013;122:2454–2454.
526.
527.
528.
Frisch SM, Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 1997;9(5):701–6.PubMed
529.
Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5(10):816–26.PubMed
530.
Guadamillas MC, Cerezo A, del Pozo MA. Overcoming anoikis—pathways to anchorage-independent growth in cancer. J Cell Sci. 2011;124(19):3189–97.PubMed
531.
Smets FN et al. Loss of cell anchorage triggers apoptosis (anoikis) in primary mouse hepatocytes. Mol Genet Metab. 2002;75(4):344–52.PubMed
532.
Tanaka K et al. Neurotrophic receptor, tropomyosin‐related kinase B as an independent prognostic marker in gastric cancer patients. J Surg Oncol. 2009;99(5):307–10.PubMed
533.
Douma S et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430(7003):1034–9.PubMed
534.
Kenific CM, Thorburn A, Debnath J. Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol. 2010;22(2):241–5.PubMedCentralPubMed
535.
Meng S et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10(24):8152–62.PubMed
536.
Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ. 2009;16(5):664–73.PubMed
537.
Schempp CM et al. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol Cancer Ther. 2014;13(4):926–37.PubMed
538.
Klubo-Gwiezdzinska J et al. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer. 2012;19(3):447–56.PubMed
539.
Fidler IJ et al. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3(1):53–7.PubMed
540.
Korb T et al. Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp Cell Res. 2004;299(1):236–47.PubMed
541.
Avvisato CL et al. Mechanical force modulates global gene expression and β-catenin signaling in colon cancer cells. J Cell Sci. 2007;120(15):2672–82.PubMed
542.
Chiu J-J, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev. 2011;91(1):327–87.PubMed
543.
Barnes JM, Nauseef JT, Henry MD. Resistance to fluid shear stress is a conserved biophysical property of malignant cells. PLoS One. 2012;7(12):e50973.PubMedCentralPubMed
544.
Swartz MA, Lund AW. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer. 2012;12(3):210–9.PubMed
545.
Pedersen JA, Boschetti F, Swartz MA. Effects of extracellular fiber architecture on cell membrane shear stress in a 3D fibrous matrix. J Biomech. 2007;40(7):1484–92.PubMed
546.
Burdick MM et al. Colon carcinoma cell glycolipids, integrins, and other glycoproteins mediate adhesion to HUVECs under flow. Am J Physiol-Cell Physiol. 2003;284(4):C977–87.PubMed
547.
Mitchell MJ, King MR. Computational and experimental models of cancer cell response to fluid shear stress. Front Oncol. 2013;3:44.PubMedCentralPubMed
548.
549.
Ruffell B et al. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010;21(1):3–10.PubMedCentralPubMed
550.
Garcia‐Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195(3):346–55.PubMed
551.
Luo J-L, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death—a new approach to cancer therapy. J Clin Invest. 2005;115(10):2625–32.PubMedCentralPubMed
552.
Kim S et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102–6.PubMedCentralPubMed
553.
Bonecchi R et al. Chemokines and chemokine receptors: an overview. Front Biosci (Landmark edition). 2008;14:540–51.
554.
Lee BJ et al. Tissue factor is involved in retinoblastoma cell proliferation via both the Akt and extracellular signal-regulated kinase pathways. Oncol Rep. 2011;26(3):665.PubMed
555.
Liu Y et al. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res. 2011;71(20):6492–502.PubMed
556.
Versteeg HH et al. Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med. 2004;10(1–6):6.PubMedCentralPubMed
557.
558.
Welsh J et al. Tissue factor expression determines tumour cell coagulation kinetics. Int J Lab Hematol. 2012;34(4):396–402.PubMed
559.
Breij EC et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 2014;74(4):1214–26.PubMed
560.
Belloc C et al. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer. 1995;60(3):413–7.PubMed
561.
Erpenbeck L et al. Inhibition of platelet GPIbα and promotion of melanoma metastasis. J Invest Dermatol. 2009;130(2):576–86.PubMed
562.
Shau H, Roth M, Golub S. Regulation of natural killer function by nonlymphoid cells. Nat Immun. 1992;12(4–5):235–49.
563.
Kopp H-G, Placke T, Salih HR. Platelet-derived transforming growth factor-β down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69(19):7775–83.PubMed
564.
Bambace N, Holmes C. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–49.PubMed
565.
Placke T et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8.PubMed
566.
Palumbo J.S. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. in Seminars in thrombosis and hemostasis. 2008. © Thieme Medical Publishers.
567.
Coupland LA, Chong BH, Parish CR. Platelets and p-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 2012;72(18):4662–71.PubMed
568.
Jurasz P. D. Alonso‐Escolano, and M.W. Radomski, Platelet–cancer interactions: mechanisms and pharmacology of tumour cell‐induced platelet aggregation. Br J Pharmacol. 2004;143(7):819–26.PubMedCentralPubMed
569.
Toliopoulos IK et al. Resveratrol diminishes platelet aggregation and increases susceptibility of K562 tumor cells to natural killer cells. Indian J Biochem Biophys. 2013;50(1):14–8.PubMed
570.
Amirkhosravi A et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003;90(3):549–54.PubMed
571.
572.
Strell C, Entschladen F. Extravasation of leukocytes in comparison to tumor cells. Cell Commun Signal. 2008;6(10):5.
573.
Schlüter K et al. Organ-specific metastatic tumor cell adhesion and extravasation of colon carcinoma cells with different metastatic potential. Am J Pathol. 2006;169(3):1064–73.PubMedCentralPubMed
574.
575.
Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005;437(7058):497–504.PubMed
576.
Colmone A et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322(5909):1861–5.PubMed
577.
Kienast Y et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16(1):116–22.PubMed
578.
Heyder C et al. Visualization of tumor cell extravasation. Contrib Microbiol. 2006;13:200–8.PubMed
579.
Kim J-E et al. RGD peptides released from βig-h3, a TGF-β-induced cell-adhesive molecule, mediate apoptosis. Oncogene. 2003;22(13):2045–53.PubMed
580.
Padua D et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133(1):66–77.PubMedCentralPubMed
581.
Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16(24):5928–35.PubMedCentralPubMed
582.
Fidler IJ, Poste G. The “seed and soil” hypothesis revisited. Lancet Oncol. 2008;9(8):808.PubMed
583.
Fidler IJ et al. The brain microenvironment and cancer metastasis. Mol Cells. 2010;30(2):93–8.PubMed
584.
Trinh VA, Hwu W-J. Chemoprevention for brain metastases. Curr Oncol Rep. 2012;14(1):63–9.PubMed
585.
Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997;80(S8):1529–37.PubMed
586.
Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70(14):5649–69.PubMedCentralPubMed
587.
Mathot L, Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci. 2012;103(4):626–31.PubMed
588.
Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 2007;28(3):297–321.PubMed
589.
Fidler IJ, Kripke ML. Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet. 2003;34(1):23–23.PubMed
590.
Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans. 2004;32:397–402.PubMed
591.
Müller A et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6.PubMed
592.
593.
Naumov GN et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 2002;62(7):2162–8.PubMed
594.
595.
Udagawa T. Tumor dormancy of primary and secondary cancers. Apmis. 2008;116(7‐8):615–28.PubMed
596.
Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett. 2010;294(2):139–46.PubMed
597.
Baeriswyl V. and Christofori G. The angiogenic switch in carcinogenesis. in Seminars in cancer biology. 2009. Elsevier.
598.
Watnick RS et al. RETRACTED: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003;3(3):219–31.PubMed
599.
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):p. 353–364.PubMed
600.
Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol. 2012;10(1):41–51.PubMed
601.
Barkan D et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 2008;68(15):6241–50.PubMedCentralPubMed
602.
Bragado P. et al., Microenvironments dictating tumor cell dormancy, in Minimal residual disease and circulating tumor cells in breast cancer. 2012, Springer. p. 25-39.
603.
Aguirre-Ghiso JA et al. Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001;12(4):863–79.PubMedCentralPubMed
604.
Allgayer H, Aguirre‐ghiso JA. The urokinase receptor (u‐PAR)—a link between tumor cell dormancy and minimal residual disease in bone marrow? Apmis. 2008;116(7‐8):602–14.PubMedCentralPubMed
605.
Kren A et al. Increased tumor cell dissemination and cellular senescence in the absence of β1‐integrin function. EMBO J. 2007;26(12):2832–42.PubMedCentralPubMed
606.
Teng MW et al. Immune-mediated dormancy: an equilibrium with cancer. J Leukocyte Biol. 2008;84(4):988–93.PubMed
607.
Moserle L, Amadori A, Indraccolo S. The angiogenic switch: implications in the regulation of tumor dormancy. Curr Mol Med. 2009;9(8):935–41.PubMed
608.
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–60.PubMed
609.
Chambers AF. Influence of diet on metastasis and tumor dormancy. Clin Exp Metastasis. 2009;26(1):61–6.PubMed
610.
Gewirtz DA. Autophagy, senescence and tumor dormancy in cancer therapy. Autophagy. 2009;5(8):1232–4.PubMed
611.
Troyanovsky B et al. Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol. 2001;152(6):1247–54.PubMedCentralPubMed
612.
Zhang X et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat Commun. 2014;5:3295.PubMedCentralPubMed
613.
El Touny LH et al. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Invest. 2014;124(1):156–68.PubMedCentralPubMed
614.
Perren TJ et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.PubMed
615.
O’Reilly MS et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315–28.PubMed
616.
O’Reilly MS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–85.PubMed
617.
Folkman J. Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res. 2006;312(5):594–607.PubMed
618.
Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A. 1998;95(11):6343–8.PubMedCentralPubMed
619.
Hahnfeldt P et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res. 1999;59(19):4770–5.PubMed
620.
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273–86.PubMed
621.
622.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31.PubMed
623.
Benzekry S, Gandolfi A, Hahnfeldt P. Global dormancy of metastases due to systemic inhibition of angiogenesis. PLoS One. 2014;9(1):e84249.PubMedCentralPubMed
624.
Livant DL et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res. 2000;60(2):309–20.PubMed
Metadata
Title
Metastasis review: from bench to bedside
Authors
Ali Mohammad Alizadeh
Sadaf Shiri
Sadaf Farsinejad
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2421-z

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis

Research Article

Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma

Research Article

MicroRNAs as novel biomarkers in the diagnosis of non-small cell lung cancer: a meta-analysis based on 20 studies

Research Article

Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis

Research Article

Silencing of Src by siRNA inhibits laryngeal carcinoma growth through the Src/PI-3 K/Akt pathway in vitro and in vivo

Review

Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits